ProQR Therapeutics NV (NASDAQ:PRQR) Receives Consensus Recommendation of “Buy” from Brokerages

ProQR Therapeutics NV (NASDAQ:PRQR) has been given a consensus recommendation of “Buy” by the eight research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $27.00.

PRQR has been the subject of a number of recent analyst reports. ValuEngine raised ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of ProQR Therapeutics in a research note on Friday, October 11th. Royal Bank of Canada reaffirmed a “buy” rating and set a $27.00 price objective on shares of ProQR Therapeutics in a report on Sunday, August 11th. Finally, BidaskClub upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 21st.

Shares of PRQR stock traded down $0.43 during trading on Thursday, reaching $8.02. The company had a trading volume of 13,394 shares, compared to its average volume of 354,464. The firm’s 50 day simple moving average is $7.39 and its two-hundred day simple moving average is $8.47. ProQR Therapeutics has a one year low of $5.49 and a one year high of $19.94. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.01 and a quick ratio of 7.01. The company has a market capitalization of $417.18 million, a PE ratio of -6.25 and a beta of 0.28.

A number of large investors have recently made changes to their positions in PRQR. Tower Research Capital LLC TRC acquired a new position in shares of ProQR Therapeutics during the second quarter worth approximately $79,000. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $92,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of ProQR Therapeutics by 23.1% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,535 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,979 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of ProQR Therapeutics by 62.3% during the 2nd quarter. Virtus ETF Advisers LLC now owns 24,216 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 9,291 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of ProQR Therapeutics by 12.6% during the 2nd quarter. Northern Trust Corp now owns 38,742 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 4,345 shares during the period. Hedge funds and other institutional investors own 43.89% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Read More: After-Hours Trading

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.